Antipsychotic polypharmacy in clozapine resistant schizophrenia: A randomized controlled trial of tapering antipsychotic co-treatment

Mental Illness

Volumn 4, Issue 1, 2012, Pages 1-4

  Repo Tiihonen, Eila ^a   Hallikainen, Tero ^a   Kivistö, Päivi ^a   Tiihonen, Jari ^a,b,c,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d VANHA VAASA HOSPITAL   (Finland)

Author keywords

Antipsychotics; Clozapine; Clozapine resistant schizophrenia; Polypharmacy; Randomized controlled trial.

Indexed keywords

CLOZAPINE; OLANZAPINE; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HOSPITAL PATIENT; HUMAN; MALE; MENTAL DISEASE; MENTAL INFLEXIBILITY; MONOTHERAPY; MOOD CHANGE; POLYPHARMACY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT;

EID: 84864828608     PISSN: 20367457     EISSN: 20367465     Source Type: Journal    
DOI: 10.4081/mi.2012.e1     Document Type: Article

References (13)

1. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
2. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911.
3. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24: 62-7.
4. Meltzer HY. Treatment of the neurolepticnonresponsive schizophrenic patient. Schizophr Bull 1992;18:515-42.
5. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11: 313-27.
6. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007;27:198-204.
7. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-57.
8. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-25.
9. Barbui C, Signoretti A, Mulè S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009;35:458-68.
10. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11.
11. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J. Clin Psychiatry 2010; 71:1115-24.
12. American Psychiatric Association. The global assessment of functioning (GAF). APA 1987.
13. Guy W. ECDEU assessment manual for psychopharmacology. Rockville: US Department of Health, Education, and Welfare; 1976. pp. 217-222.